PHARMACOTHERAPY OF POSTTRAUMATIC-STRESS-DISORDER WITH A NOVEL PSYCHOTROPIC

This was a multicenter, randomized, doable-blind, parallel trial condu cted in outpatients in three Eo countries. Following screening and pla cebo washout, patients received brofaromine (a combined MAO-A inhibito r/5-HT transport inhibitor) or placebo in a flexible dosing design. Ba sed upon the CAPS, a standardized post-traumatic stress disorder (PTSD ) interview, findings from a cohort involving both subchronic and chro nic traumatic stress marginally favored brofaromine over placebo; howe ver not to a statistically significant degree. With a more conservatio n definition of the syndrome, employing a primary cohort of patients w ith PTSD of one year or greater duration, brofaromine significantly re duced PTSD symptoms in comparison with placebo. in all analyses a subs tantial proportion of patients in both drug and placebo groups remaine d symptomatic throughout. Findings mere supported try an analysis of s econdary measures. Brofaromine may be of benefit in the therapy of PTS D.